Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1995-8-29
|
| pubmed:abstractText |
Megakaryocyte growth and development factor (MGDF) administered intraperitoneally (IP) to mice causes a dose-dependent thrombocytosis accompanied by a decrease in mean platelet volume. MGDF increases the number of megakaryocytes in the bone marrow and spleen. MGDF does not affect the circulating number of leukocytes. Carboplatin, a chemotherapeutic agent that causes thrombocytopenia in humans, administered to mice as a single IP injection at a nonlethal dose causes a significant, but reversible thrombocytopenia. The carboplatin-induced thrombocytopenia is accompanied by an increase in circulating endogenous MGDF that precedes the return of circulating platelets to a normal level. MGDF mRNA is constitutively present in the liver. After carboplatin treatment, hepatic MGDF mRNA does not increase in concordance with circulating MGDF. Circulating soluble MGDF receptor levels (c-mpl) do not change significantly during the course of carboplatin-induced thrombocytopenia. MGDF injected IP once daily beginning 1 day after injection of carboplatin reverses carboplatin-induced thrombocytopenia in a dose-dependent fashion. The normalization of circulating platelet numbers in carboplatin plus MGDF-treated mice is accompanied by a normalization of megakaryocyte numbers in the bone marrow. In conclusion, MGDF, by increasing the number of marrow megakaryocytes and circulating platelets is an effective therapy for carboplatin-induced thrombocytopenia in mice.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0006-4971
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
86
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
971-6
|
| pubmed:dateRevised |
2003-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:7620187-Animals,
pubmed-meshheading:7620187-Bone Marrow Cells,
pubmed-meshheading:7620187-Carboplatin,
pubmed-meshheading:7620187-Dose-Response Relationship, Drug,
pubmed-meshheading:7620187-Hematopoiesis,
pubmed-meshheading:7620187-Megakaryocytes,
pubmed-meshheading:7620187-Mice,
pubmed-meshheading:7620187-Mice, Inbred BALB C,
pubmed-meshheading:7620187-Platelet Count,
pubmed-meshheading:7620187-Recombinant Proteins,
pubmed-meshheading:7620187-Thrombocytopenia,
pubmed-meshheading:7620187-Thrombopoietin
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice.
|
| pubmed:affiliation |
Amgen Inc., Thousand Oaks, CA 91320, USA.
|
| pubmed:publicationType |
Journal Article
|